Unknown OBSERVATIONAL NCT05649163

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

A Non-interventional, Multi-cohort, Multi-center, Prospective Real-world Study of Treatment Pattern and Clinical Outcomes in Patients With HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

Sponsor: RemeGen Co., Ltd.

Conditions Advanced Gastric Cancer Advanced Gastroesophageal Junction Adenocarcinoma Advanced Solid Tumor HER2

Interventions Disitamab Vedotin

Updated 4 times since 2023 Last updated: Dec 14, 2022 Started: Jan 31, 2023 Primary completion: Jan 31, 2025 Completion: May 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Advanced Gastric Cancer and Advanced Gastroesophageal Junction Adenocarcinoma, this trial is ongoing. The trial is conducted by RemeGen Co., Ltd. and has accumulated 4 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Jun 2025 — Present [monthly]

Unknown

Status: Not Yet Recruiting → Unknown
Sep 2024 — Jun 2025 [monthly]

Not Yet Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting
Jan 2023 — Jul 2024 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

RemeGen Co., Ltd.
Shen Lin

Data source: Peking University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China